News

Vision-Sciences has also announced Health Canada approval for these scopes. With Health Canada’s approval, and the approval of applicable technical files and updated EC certificates, Vision-Sciences is now

This Phase III multi-center study is led by the National Cancer Institute (NCI) and is enrolling at cancer centers throughout the US. Delcath has finalized a clinical research

Schering-Plough has licensed to ViroDefense the exclusive rights for development of a specific compound series for polio indications. The license was provided in exchange for the purchase of

The companies have also announced that they have received approval from the regulatory authorities in Denmark to initiate a second repeat-dose Phase I clinical trial of TB-403 in

These tests join Xpert MRSA, which received Health Canada license in January, 2008. In Mexico, Cepheid has received registration from the Secretary of Health for its GeneXpert System

The Ascent-2 trial was terminated by Novacea in November 2007 due to an unexplained imbalance of deaths between the treatment and control arms of the trial. Ascent-2 was

In this open-label, single-arm Phase II trial, women with platinum-resistant ovarian cancer were treated with up to six cycles of NOV-002 and carboplatin. Efficacy endpoints included progression-free survival

The agreement allows Proteomika to manufacture and use nucleic acid programmable protein array (NAPPA) technology at Proteomika’s facilities for its internal purposes and the performance of services to

The approvable letter identified several minor CMC deficiencies that must be addressed and rectified before final approval is granted. The majority of these items have been addressed in